排序方式: 共有40条查询结果,搜索用时 15 毫秒
1.
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits. 相似文献
2.
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits. 相似文献
3.
目的探讨重组人血管内皮抑素联合TC方案(多西紫杉醇+环磷酰胺)治疗晚期乳腺癌的近期疗效、安全性,观察治疗前、后血清血管内皮生长因子(vascular endothelial growth factor,VEGF)水平变化。方法晚期乳腺癌患者56例,随机分为观察组和治疗组各28例,治疗组应用TC方案化疗,观察组在治疗组基础上给予重组人血管内皮抑素,2组均21d为1个周期,治疗2个周期后评价不良反应与疗效。分别于治疗前及治疗2个周期后检测2组血清VEGF水平,并与同期28例健康体检者(对照组)比较。结果观察组有效率(75.0%)高于治疗组(46.4%)(P〈0.05),骨髓抑制、恶心呕吐、脱发发生率与治疗组比较差异无统计学意义(P〉0.05);观察组、治疗组治疗前血清VEGF水平均高于对照组(P〈0.05),观察组治疗后血清VEGF水平低于治疗前与治疗组(P〈0.05),治疗组治疗后血清VEGF水平与治疗前比较差异无统计学意义(P〉0.05)。结论重组人血管内皮抑制素联合TC方案治疗晚期乳腺癌可提高疗效,降低血清VEGF水平,且不增加化疗的不良反应。 相似文献
4.
背景与目的:胃癌术后复发转移严重影响患者生存情况,SOX基因是经典Wnt信号通路的调控因子,其在胃癌术后复发及转移过程中可能发挥重要作用。本研究旨在探讨胃癌术后复发、远处转移患者肿瘤组织中SOX-2、β-catenin表达情况,探讨两者在胃癌术后复发及转移的作用。方法:采用免疫组化方法检测71例经手术切除胃癌患者的肿瘤组织中SOX-2和β-catenin蛋白表达情况,并分析其与临床病理特征和无病生存时间(disease free survival,DFS)的关系。结果:SOX-2在胃癌中的表达与胃癌复发转移、淋巴结浸润及分化程度有关(P=0.011,P=0.036,P=0.034),与患者性别、年龄及T分期无关。β-catenin在胃癌中的表达与胃癌复发转移、淋巴结浸润及T分期有关(P=0.025,P=0.014,P=0.026),与分化程度、患者性别及年龄无关。且二者均呈阳性表达者其术后复发转移率高于任意单阳性者,复发转移率分别为84%(21/25)和66.7%(24/36),二者均阴性表达者其复发转移率为30%(3/10)。生存分析显示SOX-2和β-catenin的表达与患者DFS相关。结论:SOX-2、β-catenin表达可能是胃癌术后复发转移有效的预测因子,两者联合检测有利于预测胃癌患者术后复发转移。 相似文献
5.
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits. 相似文献
6.
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits. 相似文献
7.
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits. 相似文献
8.
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits. 相似文献
9.
盐酸羟考酮缓释片治疗中重度癌痛临床观察 总被引:1,自引:0,他引:1
目的观察盐酸羟考酮缓释片治疗中重度癌痛的疗效、不良反应及对患者生活质量改善情况。方法120例中重度癌痛患者,均口服盐酸羟考酮缓释片,初始剂量为10~20rag/次,1次/12h,并根据疼痛缓解程度调整剂量至理想镇痛。用药14d后观察患者疼痛数字评分法(numericalratingscale,NRS)评分、疼痛缓解率、生活质量改善及不良反应发生情况。结果治疗后NRS评分(1.46±1.13)低于治疗前(6.37±1.63)(P〈O.05);治疗后疼痛完全缓解64例,部分缓解52例,疼痛总缓解率为96.7%;治疗后生活质量评分较治疗前增高(P〈O.05);不良反应轻。结论盐酸羟考酮缓释片治疗中重度癌痛效果满意,可改善患者生活质量。 相似文献
10.
目的:从药物经济学角度对治疗晚期非小细胞肺癌的3种表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)的临床疗效和成本原效果进行评价和分析,为临床合理用药提供参考。方法118例一线采用EGFR-TKI 治疗的晚期非小细胞肺癌患者分为3组:厄洛替尼组(38例),吉非替尼组(43例)和埃克替尼组(37例),均在治疗后评价疗效和药物不良事件,并运用药物经济学的成本原效果分析法进行研究。结果厄洛替尼组、吉非替尼组、埃克替尼组的有效率分别为71.05%、74.42%和67.57%(P >0.05);药物不良事件发生率比较差异均无统计学意义(P 均>0.05)。3组的成本原效果比分别为268.30、201.63、182.28,埃克替尼组显著低于厄洛替尼组、吉非替尼组。结论本研究的3种 EGFR-TKI 用于晚期非小细胞肺癌的治疗均具有较好的治疗效果和安全性,其中埃克替尼是最经济的。 相似文献